Core Viewpoint - NRx Pharmaceuticals has entered into a binding agreement for a registered direct offering of common stock and senior secured convertible promissory notes, aiming to raise a total of $8.9 million to support its drug development and operational funding [1][7]. Financing Details - The registered direct offering is expected to generate gross proceeds of $3.5 million, with approximately 1.2 million shares being issued at $2.88 per share [1][3]. - The company plans to issue senior secured convertible promissory notes with expected gross proceeds of $5.4 million, which will have an original discount of 8% and an interest rate of 6% per annum [1][4]. Use of Proceeds - The net proceeds from the financing will be utilized for filing New Drug Applications for NRX-100 and NRX-101, launching HOPE Therapeutics, and potentially acquiring new products for the pipeline [1][2][7]. - The funding is anticipated to support operations into 2026, alongside projected product sales and potential non-dilutive funding [1][7]. Product Development - NRx Pharmaceuticals is developing NRX-100 (IV ketamine) and NRX-101, both aimed at treating suicidal depression and PTSD, with plans to file for FDA approval [9][10]. - NRX-101 has been designated as an investigational Breakthrough Therapy by the FDA for treatment-resistant bipolar depression and chronic pain [9]. Strategic Partnerships - The company has received support from Anson Funds, which has expressed confidence in NRx's mission and its potential to transform the lives of patients with suicidal depression [2].

Compliance with Nasdaq Listing Requirements - The company regained compliance with the Nasdaq Capital Market's minimum market value of listed securities (MVLS) requirement, which mandates a MVLS of at least $35 million for 10 consecutive trading days [1][2] - The company's MVLS was at least $35 million for 10 consecutive trading days, meeting the requirement on January 16, 2025 [2] - The Nasdaq Listing Qualifications Staff confirmed the matter is now closed [1][6] Company Overview and Pipeline - NRx Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapeutics for central nervous system disorders, including suicidal bipolar depression, chronic pain, and PTSD [3] - The company's lead product, NRX-101, is an FDA-designated Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain, with potential as a non-opioid treatment for chronic pain and complicated UTI [3] - NRx is preparing to file a New Drug Application (NDA) for Accelerated Approval of NRX-101 for bipolar depression and suicidality or akathisia [3] Recent Developments in Drug Development - NRx announced the initiation of filing a New Drug Application for NRX-100 (IV ketamine) for the treatment of suicidal depression, based on clinical trial results from the US National Institutes of Health and data from French health authorities [4] - The US FDA granted Fast Track Designation for the development of ketamine (NRX-100) as part of a protocol to treat patients with acute suicidality [4] Contact Information - Matthew Duffy, Chief Business Officer of NRx Pharmaceuticals and Co-Chief Executive Officer of HOPE Therapeutics, is the contact for further information [8]

Core Insights - NRx Pharmaceuticals and its subsidiary HOPE Therapeutics have appointed Mr. Michael Taylor and Ms. Anita Nunes to their Board of Directors, enhancing their leadership team [1][2][4]. Group 1: Leadership Appointments - Mr. Michael Taylor has over 25 years of experience in global credit markets, focusing on special situations and capital formation, and has held significant positions at various financial institutions [2][3]. - Ms. Anita Nunes, CEO and Co-Founder of Smith & Sauer, LLC, has more than 20 years of experience in driving transformative growth and has led a recent $27 million investment in Hope Therapeutics and NRx Pharmaceuticals [4][6]. Group 2: Company Overview - NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics for central nervous system disorders, including suicidal bipolar depression, chronic pain, and PTSD, with NRX-101 designated as a Breakthrough Therapy by the FDA [7]. - HOPE Therapeutics aims to establish a network of interventional psychiatry clinics offering innovative therapies, including ketamine and transcranial magnetic stimulation (TMS), to treat suicidal depression and related disorders [9][10].

Company Overview - HOPE Therapeutics Inc is a development stage healthcare delivery company focused on creating a network of interventional psychiatry clinics offering ketamine transcranial magnetic stimulation (TMS) and other therapies for suicidal depression and related disorders [1] - The company is developing a digital therapeutic-enabled platform to enhance the clinical benefits of NMDA-targeted drug therapy [1] - HOPE Therapeutics is a wholly-owned subsidiary of NRx Pharmaceuticals Inc [5] Key Developments - NRx Pharmaceuticals has initiated filing a New Drug Application for NRX-100 (IV ketamine) for treating suicidal depression based on clinical trial results from US National Institutes of Health and French health authorities data [2] - NRX-100 received Fast Track Designation from the US FDA for treating acute suicidality [2] - HOPE Therapeutics plans to acquire Kadima Neuropsychiatry Institute as its flagship clinic [3][5] - Dr David Feifel, founder of Kadima and a global leader in interventional psychiatry, is expected to join HOPE as Chief Medical Innovation Officer [3][6] Industry Insights - Ketamine treatment requires appropriate psychiatric supervision in controlled settings, as emphasized by Dr Feifel and supported by HOPE Therapeutics [7] - The recent death of Mathew Perry highlights the need for psychiatric centers of excellence providing ketamine and advanced treatments for depression [8] - Dr Feifel plans to bring his successful ketamine treatment methods from Kadima to the HOPE network [8] Parent Company Information - NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing NMDA platform-based therapeutics for central nervous system disorders [9] - The company is developing NRX-101, an FDA-designated Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain [9] - NRx plans to file an NDA for Accelerated Approval of NRX-101 for bipolar depression with suicidality or akathisia [9] - NRX-101 has potential as a non-opioid treatment for chronic pain and complicated UTI [9]

Management believes uplisting has the potential to provide shareholders with improved liquidity Requires NRx Pharmaceuticals to meet certain listing requirements Company has advised NASDAQ that current shares outstanding is 15.7 millionWILMINGTON, Del., Jan. 13, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) ("NRx", the "Company"), a clinical-stage biopharmaceutical company, today announced it has applied to NASDAQ to uplist the Company's securities to the NASDAQ Global Market (NASDAQ GM).Li ...

MIAMI, Jan. 10, 2025 /PRNewswire/ -- HOPE Therapeutics™, Inc., ("HOPE"), a medical and technology driven company, and a wholly-owned subsidiary of NRx Pharmaceuticals, Inc. ("NRx", and collectively with HOPE, the "Company") (Nasdaq:NRXP), today announced it conducted an investor workshop to support planned expansion of HOPE's network of interventional psychiatry practices focused on the treatment of suicidal depression and PTSD, at the Mar-A-Lago Club in Palm Beach, FL. The event was attended by Qualified ...

Stocks with Buy Rank and Strong Momentum - NRx Pharmaceuticals, Inc (NRXP) has a Zacks Rank 1 and its current year earnings estimate increased by 46.2% over the last 60 days [1] - NRx Pharmaceuticals' shares gained 79.3% over the last three months compared to the S&P 500's 4.2% gain [1] - NRx Pharmaceuticals possesses a Momentum Score of A [1] - Pro-Dex, Inc (PDEX) has a Zacks Rank 1 and its current year earnings estimate increased by 40.9% over the last 60 days [2] - Pro-Dex's shares gained 67.7% over the last three months compared to the S&P 500's 4.2% gain [2] - Pro-Dex possesses a Momentum Score of A [2] - Puma Biotechnology, Inc (PBYI) has a Zacks Rank 1 and its current year earnings estimate increased by 24% over the last 60 days [3] - Puma Biotechnology's shares gained 10.9% over the last three months compared to the S&P 500's 4.2% gain [3] - Puma Biotechnology possesses a Momentum Score of A [3]

Anticipated capital from funds managed by Smith & Sauer to augment potential bank-financing for acquisition of HOPE Therapeutics clinics and support NRx Pharmaceutical operations. Purchase of $25 million in Series A Preferred Stock in HOPE Therapeutics (non-dilutive to NRXP shareholders) convertible into 1/3 of fully diluted HOPE Therapeutics equity, with a 15% current preferred dividend (non-callable for 2 years) for planned HOPE clinic acquisitions. Purchase $2 million in NRx equity, above the most recen ...

Dura Medical, with initial clinics in Naples and Fort Myers, to anchor the HOPE network in Florida Delivers a full range of precision psychiatry services, including Ketamine and Transcranial Magnetic Stimulation (TMS), to veteran and civilian residents of Florida Stephen Durand, founder of Dura, to serve as Director of Clinic Growth for HOPE in Florida Acquisition expected to be immediately accretive to revenue and EBITDA for NRx MIAMI, Jan. 6, 2025 /PRNewswire/ -- HOPE Therapeutics, Inc., ("HOPE," the "C ...

MIAMI, Jan. 3, 2025 /PRNewswire/ -- HOPE Therapeutics, Inc., an NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) subsidiary, is inviting Qualified Institutional Investors to an investor workshop to support planned acquisitions for a national network of interventional psychiatry practices focused on treatment suicidal depression and PTSD. The Company has previously announced non-binding Letters of Intent and banking intent for initial clinic acquisitions and has disclosed its intent to acquire and integrate clinics ...